Ahmet Omma

Dr. Ahmet Omma

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SSSevinc Can Sandikci
Sevinc Can Sandikci
SCSeda Colak
Seda Colak
AOAhmet Omma
Ahmet Omma
MEMehmet E. Enecik
Mehmet E. Enecik

1 January 2017 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
AOAhmet Omma
Ahmet Omma
SSSevinc Can Sandikci
Sevinc Can Sandikci
OKOrhan Kucuksahin
Orhan Kucuksahin
MAMurat Alisik
Murat Alisik
ÖEÖzcan EREL
Özcan EREL
Omma A, et al. J Korean Med Sci. 2017 Oct;32(10):1588-1594. https://doi.org/10.3346/jkms.2017.32.10.1588

1 January 2018 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
AOAhmet Omma
Ahmet Omma
SSSevinc Can Sandikci
Sevinc Can Sandikci
SCSeda Colak
Seda Colak
DTDuygu Tecer
Duygu Tecer
ÇYçiğdem yücel
çiğdem yücel
ZOZeynep Ozbalkan
Zeynep Ozbalkan
Introduction : Behçet’s disease (BD) is a complex multisystemic inflammatory disorder which is characterized by recurrent attacks of acute inflammation. As there is no universally recognized pathognomonic laboratory marker of BD, its diagnosis is still based on clinical findings. Aim :...

14 February 2022 in Immunotherapy
Verified
Journal Article
Closed access
MEMehmet Akif Eksin
Mehmet Akif Eksin
AEAbdulsamet Erden
Abdulsamet Erden
SGSerdar Can Güven
Serdar Can Güven
BABerkan Armağan
Berkan Armağan
BOBahar Ozdemir
Bahar Ozdemir
OKOrhan Kucuksahin
Orhan Kucuksahin
Background/aim: Multiple sclerosis (MS) is a demyelinating central nervous system disorder with few cases reported to have concomitant spondyloarthritis (SpA) spectrum disorders such as ankylosing ... Plain language summary Background/aim: Multiple sclerosis (MS) is a central nervous system disorder, with rare cases reported to have associated spondyloarthritis (SpA) spectrum disorders such as r...

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Open access
AOAhmet Omma
Ahmet Omma
DTDuygu Tecer
Duygu Tecer
OKOrhan Kucuksahin
Orhan Kucuksahin
SSSevinc Can Sandikci
Sevinc Can Sandikci
FYFatih Yildiz
Fatih Yildiz
SESukran Erten
Sukran Erten
Introduction: To investigate whether there is a relationship between the European League Against Rheumatism (EULAR) outcome measures and quality of life (QoL), fatigue, anxiety and depression in patients with pSS and to define determinants which could affect quality of life. Material and...

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RBRabia Aydoğan Baykara
Rabia Aydoğan Baykara
AKAdem Küçük
Adem Küçük
ATAyça Tuzcu
Ayça Tuzcu
GTGöksel Tuzcu
Göksel Tuzcu
ECErkan Cüre
Erkan Cüre
AOAhmet Omma
Ahmet Omma
Background/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis and endothelial dysfunction in patients with AS. Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods. Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with BASDAI (p < 0.001), and BASFI (p < 0.001). Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin levels may be associated with subclinical atherosclerosis in AS.